Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma

Stefanie Fischer,Torgrim Tandstad,Gabriella Cohn-Cedermark,Constance Thibault,Bruno Vincenzi,Dirk Klingbiel,Costantine Albany,Andrea Necchi,Angelika Terbuch,Anja Lorch,Jorge Aparicio,Axel Heidenreich,Marcus Hentrich,M. Wheater,Carl W. Langberg,Olof Ståhl,Christian Daniel Fankhauser,Anis Hamid,Konstantinos Koutsoukos,Jonathan Shamash,Jeff White,Carsten Bokemeyer,Jörg Beyer,Silke Gillessen

Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma

2019

PURPOSEClinical stage I (CSI) nonseminoma (NS) is a disease limited to the testis without metastases. One treatment strategy after orchiectomy is adjuvant chemotherapy. Little is known about the ou...

Keywords:

Cisplatin
Adjuvant
treatment strategy
Pathology
Bleomycin
Internal medicine
Oncology
Chemotherapy
Etoposide
Orchiectomy
Medicine
Disease
Subsequent Relapse
Hazard ratio
Progressive disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations